These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30993097)

  • 1. "
    Langabeer SE
    J Cancer Prev; 2019 Mar; 24(1):59-60. PubMed ID: 30993097
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Letter to Editor "
    Sohrabi A
    J Cancer Prev; 2019 Mar; 24(1):61-62. PubMed ID: 30993098
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections.
    Abdolmaleki M; Sohrabi A
    J Cancer Prev; 2018 Jun; 23(2):82-86. PubMed ID: 30003068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
    Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
    Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm].
    Liu Y; Liu C; He N; Wang M; Zhang X; Tang D; Ji C; Ma D
    Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):191-5. PubMed ID: 25854460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?: Multi-Institutional Study.
    Wu X; Lee JW; Peker D; Spitzer SG; Laser J; Reddy VV; Harada S
    Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):589-94. PubMed ID: 26371429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan.
    Tabassum N; Saboor M; Ghani R; Moinuddin M
    Pak J Med Sci; 2014 Jan; 30(1):185-8. PubMed ID: 24639858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis.
    Colaizzo D; Tiscia GL; Bafunno V; Amitrano L; Vergura P; Lupone MR; Grandone E; Guardascione MA; Margaglione M
    Thromb Res; 2011 Sep; 128(3):233-6. PubMed ID: 21497883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of
    Chen M; Zhang C; Hu Z; Li Z; Li M; Wu L; Zhou M; Liang D
    Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
    Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
    Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
    Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
    Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
    Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.
    Zhou J; Ye Y; Zeng S; Zhou Y; Mao Z; Song X; Ying B; Lu X; Jiang H; Wang L
    PLoS One; 2013; 8(2):e57856. PubMed ID: 23469088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.
    Sazawal S; Bajaj J; Chikkara S; Jain S; Bhargava R; Mahapatra M; Saxena R
    Indian J Med Res; 2010 Oct; 132():423-7. PubMed ID: 20966521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
    Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
    Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
    Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
    Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.